Zhu Xuemei, Bai Yujing, Yu Wenzhen, Pan Chungting, Jin Enzhong, Song Dan, Xu Qiong, Yao Yuou, Huang Lvzhen, Tao Yong, Li Xiaoxin, Zhao Mingwei
Department of Ophthalmology, Peking University People's Hospital, Key Laboratory of Vision Loss and Restoration, Ministry of Education, Beijing Key Laboratory of Diagnosis and Therapy of Retinal and Choroid Diseases, Beijing, 100044, China.
PLoS One. 2015 Jan 24;10(1):e0115523. doi: 10.1371/journal.pone.0115523. eCollection 2015.
Pleiotrophin (PTN), a secreted, multifunctional cytokine, is involved in angiogenic, fibrotic and neurodegenerative diseases. However, little is known about its effects on diabetic retinopathy, a neurovascular disease. To investigate the role of PTN in proliferative diabetic retinopathy (PDR), PTN concentration in the vitreous was evaluated in PDR patients and non-diabetic controls. PTN expression was observed in epiretinal membranes from patients. PTN knockdown was performed using small interfering (si)RNA, and the effects on retinal pigment epithelium (RPE) cells and human umbilical vascular endothelia cells (HUVECs) were observed in vitro under hyperglycemic and hypoxic conditions. Cell attachment, proliferation, migration, tube formation, cell cycle, apoptosis, extracellular signal-regulated kinase 1/2 (ERK 1/2) phosphorylation, and VEGF levels were studied. The vitreous PTN concentration in PDR patients was higher than that in non-diabetic controls, and PTN was highly expressed in the fibrovascular membranes of PDR patients. Under hyperglycemic and hypoxic conditions, PTN knockdown reduced cell attachment, proliferation, migration, and tube formation and induced cell cycle arrest and apoptosis in vitro. Mechanically, PTN depletion decreased ERK 1/2 phosphorylation. Recombinant PTN up regulated the concentration of VEGF in vitro, which can be attenuated by the ERK 1/2 inhibitor. Taken together, our results implied that elevated PTN in PDR patients might participate in the critical processes of the development of PDR, most likely playing roles in angiogenesis and proliferation, possibly by activating the ERK 1/2 pathway and regulating VEGF secretion. These findings provide new insight into the roles of PTN in PDR and suggest that PTN may become a new target for therapeutic intervention in PDR.
多效生长因子(PTN)是一种分泌型多功能细胞因子,参与血管生成、纤维化和神经退行性疾病。然而,其对糖尿病视网膜病变(一种神经血管疾病)的影响却知之甚少。为了研究PTN在增殖性糖尿病视网膜病变(PDR)中的作用,我们评估了PDR患者和非糖尿病对照者玻璃体内的PTN浓度。在患者的视网膜前膜中观察到了PTN表达。使用小干扰(si)RNA进行PTN敲低,并在高血糖和缺氧条件下体外观察其对视网膜色素上皮(RPE)细胞和人脐血管内皮细胞(HUVECs)的影响。研究了细胞黏附、增殖、迁移、管形成、细胞周期、凋亡、细胞外信号调节激酶1/2(ERK 1/2)磷酸化和VEGF水平。PDR患者玻璃体内的PTN浓度高于非糖尿病对照者,且PTN在PDR患者的纤维血管膜中高表达。在高血糖和缺氧条件下,PTN敲低可减少体外细胞黏附、增殖、迁移和管形成,并诱导细胞周期停滞和凋亡。机制上,PTN缺失可降低ERK 1/2磷酸化。重组PTN在体外上调VEGF浓度,而ERK 1/2抑制剂可减弱这种上调作用。综上所述,我们的结果表明,PDR患者中升高的PTN可能参与了PDR发展的关键过程,最有可能在血管生成和增殖中发挥作用,可能是通过激活ERK 1/2途径和调节VEGF分泌。这些发现为PTN在PDR中的作用提供了新的见解,并表明PTN可能成为PDR治疗干预的新靶点。